Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose
escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients
with a malignant solid tumor or lymphoma.